Galderma

Galderma is a pharmaceutical company that concentrates on the research, development, and commercialisation of dermatological products. Its portfolio includes prescription treatments for conditions such as acne, psoriasis, rosacea and actinic keratosis, as well as over‑the‑counter skin care lines. The company produces topical creams, gels, oral medications and light‑based therapies that are used by dermatologists and general practitioners. Galderma’s brands are distributed through pharmacies, hospitals and direct‑to‑consumer channels in many markets.

Although specific employee or revenue figures are not provided in the source material, Galderma operates on an international scale with a presence across multiple continents. The company collaborates with healthcare providers, research institutions and regulatory bodies to bring new skin‑health therapies to market. Its global reach allows it to address diverse dermatological needs in varied clinical settings.

Galderma’s distinguishing attribute is its dedicated focus on dermatology, which enables specialised expertise in skin disease pathology and treatment innovation. The firm maintains regulatory compliance with agencies such as the Swissmedic, the U.S. FDA and the European EMA, supporting its product approvals worldwide. Headquartered in Switzerland, the company benefits from the country’s strong pharmaceutical ecosystem and access to skilled scientific talent.